You are here

FDA Urges Caution With Robotically Assisted Surgical Devices

Safety Risks for Patients Undergoing Mastectomies and Cancer Surgeries

The Food and Drug Administration (FDA) has warned against the use of robotically assisted devices for mastectomies and other cancer surgeries, stating that the products  may pose safety risks and result in poor outcomes for patients.

The agency said it decided to issue its warning after reviewing studies suggesting that robotically assisted devices were being used to perform cancer procedures for which there is limited data on their safety and effectiveness.

One recent study in the New England Journal of Medicine reported that use of the devices in radical hysterectomies in women with cervical cancer was associated with lower rates of disease-free survival and overall survival than traditional surgery.

The FDA also urges patients to discuss the risks, benefits, and alternative procedure options with their doctors before making treatment decisions, and to ask their doctors about their training, experience, and outcomes of patients they have treated with robotically assisted surgery.

Source: FDA, February 28, 2019

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage